



MacroGenics, Inc.
Investor Relations Department
9640 MEDICAL CENTER DRIVE
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: MGNX


Last Trade:	17.05
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.17 ▲ (+1.007%)
Day Range	16.70 - 17.09
52-Week Range	14.36 - 32.68
Volume	197,645

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceu... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 10, 2017 [Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Presented at ESMO Congress 2017](#)
- Sep 5, 2017 [MacroGenics Advances Two First-in-Class Clinical DART® Molecules](#)
- Aug 31, 2017 [MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen](#)
- Aug 30, 2017 [MacroGenics to Participate in Three Investor Conferences in September](#)
- Aug 9, 2017 [MacroGenics to Present at the Webbush PacGrow Healthcare Conference](#)

Upcoming Events [\[View all \]](#)

- Sep 28, 2017 2:00 PM ET [LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology](#)
- Feb 28, 2017 [Annual Report \(10-K\)](#)
- Apr 4, 2017 [Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017 [Quarterly Report \(10-Q\)](#)
- May 3, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 2, 2016 [Quarterly Report \(10-Q\)](#)